monitor
proteom
differ
bacteri
viral
pathogenesi
allow
direct
comparison
strain
variabl
sever
infect
environment
influenc
effect
genet
manipul
primarili
carri
pathogen
bacteria
use
gel
electrophoresi
usual
involv
strain
exhibit
divers
phenotyp
includ
antivir
drug
resist
alter
degre
infect
pathogen
differ
growth
condit
differenti
genotyp
low
mass
rang
protein
display
method
matrixassist
laser
desorptionion
maldi
timeofflight
tof
mass
spectrometri
ms
surfaceenhanc
laser
desorptionion
seldi
tofm
also
increasingli
appli
microbi
system
compar
proteom
techniqu
isotopecod
affin
tag
icat
well
differ
multidimension
chromatographi
system
util
frontend
step
prior
ms
recent
ms
platform
fourier
transform
ion
cyclotron
reson
fticr
ms
also
appli
microbi
system
practic
type
lysat
fraction
deriv
escherichia
coli
frequent
util
character
differ
ms
platform
thu
surpris
proteom
public
biodefens
pathogen
involv
differenti
character
multipl
bacteri
proteom
tabl
summari
repres
list
differ
niaid
prioriti
pathogen
analyz
type
multidimens
separ
compar
display
method
follow
ms
sequenc
differenti
express
protein
present
list
intend
exhaust
scope
reflect
recent
proteom
character
studi
indic
prioriti
pathogen
includ
tabl
one
common
approach
use
studi
list
tabl
involv
separ
step
differenti
express
protein
target
identifi
excis
elut
gel
digest
trypsin
amino
acid
sequenc
tryptic
peptid
determin
use
differ
maldi
instrument
configur
electrospray
iontrap
mass
spectromet
type
hybrid
instrument
contrast
sophist
affinitybas
technolog
icat
underrepres
tabl
like
increasingli
appli
microbi
system
overal
type
studi
list
tabl
illustr
rang
exampl
achiev
differ
frontend
separ
comparison
method
singl
method
current
superior
within
current
framework
rapidli
evolv
area
proteom
technolog
choic
method
appli
larg
depend
budgetari
proteom
resourc
avail
individu
investig
given
institut
organ
tabl
prioriti
pathogen
becom
candid
organ
genom
sequenc
effort
illustr
effect
human
genom
linkag
proteom
tryptic
databas
search
engin
facilit
direct
peptid
sequenc
ident
bacteri
genom
databas
organ
character
differenti
protein
express
greatli
enhanc
success
effort
regard
multitud
genom
databas
resourc
microb
exist
continu
rapidli
evolv
bacteri
genom
ad
databas
includ
avail
institut
genom
research
md
usa
max
planck
institut
germani
site
access
via
internet
also
summar
separ
public
anoth
critic
evolv
resourc
searchabl
polyacrylamid
gel
electrophoresi
page
imag
databas
differ
pathogen
differ
host
cell
type
typifi
includ
ident
migrat
posit
alreadi
character
protein
refer
gel
similar
less
preval
icat
refer
databas
differ
organ
also
establish
type
databas
resourc
greatli
decreas
redund
sequenc
everi
protein
gel
icat
analysi
lastli
compar
bacteri
proteom
studi
could
analyz
use
anoth
emerg
technolog
differenti
ingel
fluoresc
electrophoresi
dige
involv
differenti
label
two
relat
protein
sampl
differ
color
dye
separ
sampl
mixtur
label
third
refer
dye
follow
separ
mixtur
standard
gel
alreadi
report
analysi
e
coli
like
play
increas
role
type
bacteri
proteom
character
studi
use
selditof
proteincaptur
chip
surfac
malditof
direct
applic
sampl
spot
plate
simultan
analysi
popul
protein
present
complex
biolog
materi
yield
profil
uniqu
specif
sampl
contrast
gel
strategi
seldi
maldi
approach
rapid
highthroughput
capabl
autom
assay
develop
requir
order
magnitud
lower
amount
protein
sampl
effect
resolv
lowmass
protein
da
restrict
mass
rang
disadvantag
comprehens
proteom
analysi
requir
approach
much
better
accomplish
gel
fticrm
method
mass
valu
multipl
potenti
biomark
identifi
seldi
approach
major
limit
seldi
use
effici
direct
amino
acid
sequenc
determin
biomark
candid
necessit
use
strategi
purpos
new
gener
malditoftof
instrument
emerg
facilit
identif
preval
peptid
fragment
less
masstocharg
ratio
thu
increas
type
proteom
profil
strategi
appli
biodefens
pathogen
exampl
appli
maldi
biodefens
pathogen
character
summar
follow
paragraph
exampl
seldi
applic
present
next
section
multipl
msbase
studi
report
character
uniqu
sporul
veget
properti
bacillu
spp
particularli
bacillu
anthraci
b
anthraci
strain
found
throughout
world
howev
wide
geograph
distribut
reflect
great
genet
divers
except
document
variabl
number
tandem
repeat
sequenc
singl
nucleotid
polymorph
use
phylogenet
relationship
genet
differ
import
understand
pathogenesi
b
anthraci
proteom
method
appli
identif
protein
differenti
express
variou
cultur
condit
cours
infect
forens
biodefens
perspect
proteom
profil
approach
may
abl
identifi
uniqu
protein
signatur
specif
relat
spore
cultur
condit
well
differ
virul
strain
b
anthraci
b
anthraci
spore
coat
surround
hydrophob
balloonlik
glycoprotein
shell
term
exosporium
multipl
studi
describ
differ
protein
compon
exosporium
specif
protein
includ
collagenlik
structur
protein
term
bcla
intergr
membran
glycoprotein
multipl
embed
solubl
protein
racemas
superoxid
dismutas
comprehens
analysi
thu
far
differ
protein
endospor
b
anthraci
stern
identifi
multidimension
chromatographi
tandem
ms
sequenc
method
given
complex
growth
variabl
spore
proteom
mani
strain
b
anthraci
higher
throughput
maldi
profil
strategi
could
provid
broader
complementari
inform
base
develop
countermeasur
divers
anthrax
strain
exampl
malditof
analysi
tryptic
fragment
small
acidsolubl
spore
protein
bacillu
spp
proven
diagnost
differ
within
speci
anoth
malditof
studi
report
differenti
profil
lowmass
peptidesprotein
could
determin
spore
protein
differ
b
anthraci
strain
compar
two
recent
report
evalu
abil
convent
malditof
approach
new
hybrid
iontrap
malditof
instrument
rapidli
separ
identifi
mixtur
peptid
deriv
limit
tryptic
proteolysi
mix
spore
five
bacillu
spp
follow
onprob
digest
immobil
trypsin
cleavag
product
limit
set
bacteri
protein
molecular
mass
approxim
kda
obtain
within
min
bacteri
peptid
suitabl
isol
highenergi
fragmentaion
analysi
gener
within
min
sequenc
peptid
allow
rapid
identif
abund
protein
present
bacteri
sourc
use
standard
databas
search
speciesspecif
tryptic
peptid
could
gener
bacillu
spp
studi
relat
studi
novel
quadrupol
iontrap
tofm
use
analyz
peptid
sequenc
gener
proteolyz
spore
mixtur
report
use
method
onprob
solubil
situ
proteolyt
digest
small
acidsolubl
spore
protein
differ
speci
present
mixtur
could
identifi
less
min
hybrid
instrument
result
mass
resolv
power
maldi
mass
accuraci
part
per
million
use
iontrap
tof
tandem
configur
sequencespecif
inform
isol
proton
peptid
store
ion
trap
gain
via
tandem
ms
experi
averag
mass
resolv
power
product
ion
analysi
cumul
malditof
studi
illustr
potenti
appli
mass
spectromet
potenti
field
applic
quickli
resolv
identifi
complex
mixtur
microb
reflect
given
environ
genom
inform
becom
avail
differ
pathogen
bacteria
well
bacteria
present
normal
given
system
approach
could
critic
multipl
biodefens
applic
emerg
first
respond
scenario
selditofm
technolog
recent
develop
facilit
protein
profil
complex
biolog
mixtur
modif
malditof
technolog
use
proteinchip
array
coat
chemic
surfac
eg
ionic
hydrophob
metal
affin
captur
protein
molecul
complex
mixtur
retain
protein
subsequ
analyz
tofm
aid
seldi
softwar
retent
map
gener
depict
masstocharg
ratio
correspond
molecular
weight
process
expand
mani
hundr
sampl
populationspecif
protein
express
profil
deduc
characterist
assay
group
result
fingerprint
pattern
uniqu
design
group
new
strain
coronaviru
cov
identifi
caus
sever
acut
respiratori
syndrom
sar
infect
individu
led
death
worldwid
five
recent
studi
appli
proteom
profil
method
analyz
serum
plasma
cohort
collect
subset
sar
infect
patient
effort
identifi
earli
detect
prognost
biomark
three
studi
selditof
protein
chip
profil
use
distinct
sera
plasma
cohort
largest
report
studi
serum
sampl
separ
acut
sar
n
day
onset
fever
nonsar
n
cohort
larg
nonsar
cohort
includ
sampl
indic
fever
influenza
n
pneumonia
n
lung
cancer
n
healthi
control
n
sampl
incub
weak
cation
proteinchip
ciphergen
biosystem
follow
selditof
spectra
gener
peak
ident
determin
panel
four
biomark
peak
could
detect
sensit
acut
sar
specif
nonsar
sampl
four
peak
could
also
use
distinguish
acut
sar
fever
influenza
cohort
specif
conclud
approach
could
form
basi
serum
proteom
profil
assay
earli
detect
sar
infect
separ
seldi
studi
profil
longitudin
sera
sampl
collect
sar
patient
compar
sera
control
patient
without
sar
total
distinct
protein
peak
identifi
differenti
diagnost
sar
one
serum
amyloid
saa
subsequ
saa
concentr
determin
longitudin
serum
sampl
found
good
correl
saa
concentr
extent
pneumonia
small
subset
sever
sar
case
like
ident
function
properti
differ
serum
protein
marker
identifi
seldi
peak
repres
acutephas
reactant
consist
critic
proteom
profil
serum
approach
peak
reflect
innat
immun
respons
pathogenderiv
protein
suffici
studi
definit
determin
answer
question
possibl
peak
repres
possibl
without
fraction
remov
major
serum
plasma
protein
prior
seldi
analysi
like
differenti
marker
reflect
acutephas
respons
howev
preclud
use
diagnost
andor
distinct
particular
type
viral
infect
exampl
gel
studi
plasma
sampl
four
sar
patient
major
differenti
express
protein
identifi
acutephas
protein
includ
novel
marker
peroxiredoxinii
secret
tcell
author
hypothes
type
tcellderiv
marker
could
reflect
innat
immun
signal
cascad
result
sarscov
infect
much
work
remain
done
identif
lowmass
serum
biomark
applic
complex
bodi
fluidderiv
mixtur
hybrid
iontrap
maldi
instrument
describ
spore
protein
mixtur
could
facilit
effort
follow
differ
protein
display
identif
studi
mention
previous
method
could
funnel
toward
directli
adapt
develop
improv
vaccin
identifi
antigen
compon
differ
pathogen
immunoproteom
given
pathogen
consist
identifi
antigen
present
infect
host
recognit
everi
potenti
epitop
deriv
pathogen
genom
appear
requir
effect
immun
respons
occur
subset
antigen
epitop
provid
necessari
protectionneutr
electrophoresi
blot
wholecel
lysat
membraneenrich
fraction
provid
display
method
identifi
clinic
relev
subset
antigen
follow
incub
blot
pathogenexpos
sera
sampl
vivo
antigen
particular
pathogen
thu
identifi
follow
ms
sequenc
highresolut
electrophoresi
unambigu
identif
prerequisit
reliabl
result
statist
analysi
result
antigen
candid
diagnost
assay
vaccin
develop
andor
target
therapi
specif
prioriti
pathogen
list
differ
immunoproteom
studi
report
francisella
tularensi
anthrax
shigella
mycobacterium
tuberculosi
exampl
attenu
live
vaccin
strain
f
tularensi
use
gener
wholecel
lysat
integr
membran
protein
fraction
basic
protein
fraction
separ
gel
transfer
nitrocellulos
sera
collect
patient
suffer
tularemia
use
probe
immunoblot
compar
control
sera
healthi
donor
sera
patient
lyme
diseas
approach
potenti
antigen
spot
identifi
smaller
subset
select
ms
sequenc
analysi
sera
patient
tularemia
found
predomin
antigen
speci
differ
variant
chaperonin
isol
integr
membran
wholecel
lysat
anoth
exampl
recent
describ
anthrax
b
anthraci
use
sera
infect
anim
antibodi
sourc
studi
uniqu
describ
predict
comput
screen
anthrax
genom
identifi
vaccin
candid
compar
result
function
immunoproteom
assay
six
eight
protein
vivo
screen
previous
identifi
antigen
five
eight
protein
predict
comput
screen
studi
illustr
combin
resourc
avail
particular
antigen
eg
genom
proteom
immunolog
vivo
infect
model
gener
novel
vaccin
candid
prioriti
pathogen
develop
assay
system
provid
capabl
perform
type
comprehens
experiment
approach
emphas
anoth
immunoproteom
approach
focus
character
pathogenderiv
peptid
bound
major
histocompat
complex
mhc
antigenpres
cell
elicit
effector
tcell
respons
pathogen
follow
immunoaffin
purif
dissoci
bound
peptid
mhc
complex
peptid
sequenc
tandem
ms
identifi
peptid
thu
repres
potenti
vaccin
candid
pathogen
approach
recent
comprehens
review
potenti
highli
effect
coupl
comprehens
analysi
strategi
describ
preced
paragraph
author
proteom
effort
biodefens
research
within
next
year
center
develop
diagnost
assay
improv
influenza
vaccin
strategi
comprehens
character
immun
respons
influenza
viru
infect
author
believ
human
influenza
viru
ideal
model
comprehens
proteom
character
viru
import
biodefenseinfecti
diseas
threat
influenza
viru
paradigm
base
multipl
consider
attain
goal
readili
feasibl
whole
repertoir
reagent
model
avail
influenza
research
includ
welldefin
viral
stock
prepar
methodolog
cell
line
anim
infect
model
clinic
million
individu
vaccin
influenza
million
infect
natur
year
challeng
strain
defin
antibodi
detect
assay
clinic
use
antivir
agent
also
avail
cumul
obtain
statist
signific
number
research
sampl
relat
influenza
infect
andor
vaccin
straightforward
collect
incorpor
studi
protocol
exampl
author
preliminari
experi
indic
elderli
adult
lower
tcell
respons
influenza
vaccin
young
adult
reduc
respons
proport
reduc
antibodi
respons
mechan
ageassoci
declin
respons
precis
caus
senesc
lead
reduc
antibodi
respons
elderli
peopl
area
futur
research
use
differ
proteom
analys
appli
serum
immun
cell
isol
author
hope
identifi
surrog
marker
associ
either
antibodi
andor
tcell
respons
character
surrog
marker
investig
role
immun
senesc
addit
event
bioterrorist
attack
natur
outbreak
infecti
diseas
sar
earli
diagnosi
pivot
treatment
contain
outbreak
author
believ
character
identifi
host
immun
respons
infect
use
earli
diagnosi
well
new
treatment
strategi
target
harm
aspect
host
immun
respons
influenza
ideal
system
appli
current
emerg
proteom
technolog
accomplish
goal
two
exampl
recent
pilot
studi
proteom
profil
strategi
appli
vaccin
subject
present
next
section
illustr
effect
approach
could
clinic
biodefens
studi
glennan
center
va
usa
six
healthi
young
volunt
year
age
recruit
receiv
live
viru
flumist
vaccin
intranas
serum
nasal
swab
obtain
subject
immedi
day
day
post
vaccin
serum
dramat
differ
seldi
profil
observ
particularli
day
compar
day
three
chip
surfac
distinct
protein
significantli
p
underexpress
day
sera
six
flumistvaccin
subject
figur
kda
gel
view
comparison
day
flumist
recipi
present
three
chip
surfac
peak
reflect
transient
increas
decreas
day
rebound
near
day
valu
day
besid
highlight
chang
day
figur
also
illustr
use
multipl
chip
surfac
increas
avail
number
potenti
biomark
could
target
identif
sequenc
nasal
swab
sampl
obtain
time
sera
sampl
surprisingli
sampl
day
postflumist
administr
indic
differ
protein
profil
rel
day
baselin
profil
repres
profil
day
versu
day
flumist
recipi
shown
figur
note
larg
differ
intens
scale
two
sampl
signific
upregul
protein
kda
rang
lower
mass
region
within
box
kda
four
six
flumist
recipi
similar
respons
day
protein
return
baselin
day
data
shown
sodium
dodecyl
sulfategel
use
separ
swab
fluid
day
flumist
recipi
three
band
approxim
kda
excis
gel
protein
elut
trypsin
appli
lcq
decaxp
esi
mass
spectromet
thermofinnigan
kda
band
three
nonredund
peptid
match
human
palat
lung
nasal
epitheli
clone
plunc
found
plunc
newli
discov
gene
famili
similar
human
bactericidalpermeabilityincreas
protein
mammalian
lipopolysaccharidebind
lipid
transport
protein
kda
protein
sequenc
identif
hypothet
identifi
two
put
membran
protein
unknown
function
summari
intent
present
pilot
seldi
studi
flumist
vaccine
illustr
clearli
distinct
detect
biolog
differ
present
serum
nasal
swab
protein
extract
whatev
proteom
platform
avail
particular
investig
incorpor
longitudin
collect
bodi
fluid
vaccin
treatment
trial
pathogen
consid
fluid
repres
larg
uncharacter
reservoir
potenti
biomark
vaccin
efficaci
treatment
respons
diseas
progress
applic
context
util
proteom
relat
resourc
biodefens
applic
reason
great
optim
well
reason
great
concern
excel
progress
appli
develop
innov
advanc
proteom
resourc
applic
bacteri
pathogen
particularli
anthrax
clear
converg
proteom
genom
immunolog
inform
evid
hold
great
promis
design
improv
vaccin
identif
new
treatment
target
mechanist
function
inform
gain
studi
posit
impact
mani
area
human
health
research
eventu
collater
benefit
proteom
methodolog
develop
biodefens
applic
could
enorm
appli
less
pathogen
bacteri
infect
human
anim
plant
diseas
differ
environment
system
statement
base
current
proteom
technolog
sinc
one
rapidli
evolv
area
biomed
research
reason
expect
even
better
method
instrument
quickli
emerg
biodefens
applic
contrast
progress
bacteri
pathogen
applic
proteom
viral
pathogen
embarrassingli
spars
bodi
literatur
field
even
studi
relat
hiv
includ
great
caus
concern
context
bioterror
threat
public
health
gener
almost
mani
proteomicrel
report
evalu
clinic
specimen
sar
patient
report
hiv
influenza
virus
prioriti
pathogen
list
combin
even
inclus
cell
line
anim
modelrel
proteom
studi
significantli
alter
statement
clearli
improv
strategi
appli
proteom
viral
infect
need
henc
discuss
influenza
paradigm
system
includ
attempt
initi
encourag
type
studi
author
opinion
situat
reflect
larg
reactionari
research
viewpoint
whatev
infecti
diseas
bioterror
pathogen
current
news
one
hand
benefici
argument
increas
understand
anthrax
infect
develop
countermeasur
need
hope
type
studi
referenc
herein
illustr
progress
great
potenti
benefit
deriv
proteom
analys
anthrax
hand
proteom
report
sar
far
result
far
less
mortal
typic
flu
season
usa
viral
pathogen
urgent
biodefens
threat
need
wait
avian
flu
final
adapt
virul
human
strain
wors
wait
bioengin
strain
releas
initi
intens
studi
argument
forgo
critic
continu
research
sar
encourag
increas
applic
proteom
preval
andor
morbid
virus
comprehens
approach
ie
proteom
genom
immunolog
appli
anthrax
research
readili
adapt
studi
influenza
viru
hiv
mani
virus
prioriti
pathogen
list
context
biodefens
applic
next
year
bring
wealth
emerg
rapidli
expand
resourc
facilit
increas
proteom
applic
bacteri
viral
system
multidimension
separ
method
coupl
ms
analysi
tryptic
peptid
biodefenserel
bacteri
proteom
list
tabl
highlight
util
proteom
approach
one
like
continu
find
increas
use
differ
frontend
separ
technolog
emerg
obvious
microbialvir
genom
avail
differ
speci
easier
perform
function
proteom
studi
increas
gel
refer
site
also
greatli
facilit
effort
similarli
icat
refer
site
equal
critic
path
clear
applic
dige
host
futur
icat
approach
readili
accomplish
access
fticrm
instrument
increas
coupl
appropri
genom
databas
unpreced
opportun
fulli
character
proteom
individu
bacteri
pathogen
well
host
respons
viral
bacteri
infect
clinic
applic
proteom
typifi
seldi
maldi
analysi
blood
fluid
lesson
alreadi
learn
appli
technolog
develop
cancer
diagnost
includ
recent
studi
evalu
viral
hepat
condit
liver
cancer
thousand
proteom
serum
analys
perform
cancer
diagnost
cumul
experi
highlight
sever
area
need
improv
type
profil
studi
includ
establish
uniform
sampl
acquisit
process
storag
protocol
resolv
ms
instrument
peak
sensitivityresolut
issu
well
improv
data
analysi
tool
fact
issu
readili
address
activ
pursu
across
multipl
clinic
academ
biotechnolog
biopharmaceut
level
highli
encourag
issu
specif
cancerrel
studi
equal
applic
biodefens
studi
order
largescal
proteom
profil
studi
accomplish
initi
readili
avail
clinic
specimen
associ
biodefens
pathogen
influenza
addit
consider
mention
whenev
clinic
trial
design
prospect
sampl
collect
includ
studi
design
particularli
blood
draw
alreadi
like
compon
depend
studi
avail
fluid
also
collect
eg
urin
nasal
fluid
saliva
anoth
approach
would
use
archiv
sampl
previou
clinic
trial
either
way
necessari
accomplish
type
studi
creat
integr
collabor
framework
protein
chemist
mass
spectroscopist
sampl
acquisit
biorepositori
staff
biostatistician
epidemiologist
clinicianspathologist
patient
cooper
consent
defici
individu
categori
compromis
outcom
entir
project
assay
level
need
continu
develop
highthroughput
reproduc
protein
fraction
procedur
identifi
potenti
lowconcentr
protein
biomark
key
achiev
develop
inter
intrainstitut
translat
research
group
bring
togeth
necessari
resourc
capit
immens
promis
proteom
technolog
applic
biodefens
relat
research
